Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma

Expert Review of Vaccines

Volumn 13, Issue 3, 2014, Pages 377-385

  Fenstermaker, Robert A ^a   Ciesielski, Michael J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Vaccine

Indexed keywords

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; GLIOMA; HUMANS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; VACCINATION;

EID: 84894065014     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.881255     Document Type: Review

References (75)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS Statistical Report: primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14(Suppl 5):v1-v49
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96 . This review describes the results of standard therapy for glioblastoma.
3. Giese A, Westphal M. Treatment of malignant glioma: a problem beyond the margins of resection. J Cancer Res Clin Oncol 2001;127(4):217-25
4. Aguilar LK, Arvizu M, Aguilar-Cordova E, Chiocca EA. The spectrum of vaccine therapies for patients with glioblastoma multiforme. Curr Treat Options Oncol 2012;13(4):437-50
5. Thomas AA, Ernstoff MS, Fadul CE. Immunotherapy for the treatment of glioblastoma. Cancer J 2012;18(1):59-68
6. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987;84(19):6899-903
7. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89(7):2965-9
8. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55(23):5536-9
9. Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 2012;7:93-103 . This review summarizes the evidence to date for use of CDX-110 to treat glioblastoma multiforme.
10. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20(4): 1063-8
11. Uematsu M, Ohsawa I, Aokage T, et al. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 2005;72(3): 231-8
12. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19(5):617-23
13. Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors. Cancer 2003;97(4):1077-83
14. Sasaki T, Lopes MB, Hankins GR, Helm GA. Expression of survivin an inhibitor of apoptosis protein in tumors of the nervous system. Acta Neuropathol (Berl) 2002;104(1):105-9
15. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396(6711):580-4
16. Rosa J, Canovas P, Islam A, et al. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 2006;17(3):1483-93
17. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000;19(29):3225-34
18. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58(23):5315-20
19. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40(4):1117-23
20. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152(1):43-9
21. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3(1):46-54
22. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006;5(5): 1087-98
23. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002;5(2): 65-72
24. Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60(7):1815-17
25. Andersen MH, Pedersen LO, Capeller B, et al. Spontaneous cytotoxic T-cell responses against survivin-derived, MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61(16):5964-8
26. Hadrup SR, Gehl J, Sorensen RB, et al. Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther 2006; 5(5):480-2
27. Kim C-H, Woo S-J, Park JS, et al. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 2007;122(4): 615-22
28. Ciesielski MJ, Apfel L, Barone TA, et al. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 2006;55(12): 1491-503
29. Xiang R, Mizutani N, Luo Y, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005;65(2):553-61
30. Ciesielski MJ, Ahluwalia MS, Munich SA, et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 2010;59(8): 1211-21 . This review explains the scientific basis behind active specific vaccination against survivin using Survivin vaccine.
31. Wang YQ, Zhang HH, Liu CL, et al. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/ MPL adjuvant in a murine melanoma model. Int Immunopharmacol 2013;17(1): 9-17
32. Otto K, Andersen MH, Eggert A, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005;23(7):884-9
33. Wobser M, Keikavoussi P, Kunzmann V, et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006;55(10):1294-8
34. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2(1):19
35. ClinicalTrials.gov identifier: NCT01416038. Available from: http://clinicaltrials.gov/show/ NCT01416038
36. Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol 2000;20(6):433-50
37. Lohr J, Knoechel B, Nagabhushanam V, Abbas AK. T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol Rev 2005;204:116-27
38. Fikes JD, Sette A. Design of multi-epitope, analogue-based cancer vaccines. Expert Opin Biol Ther 2003;3(6):985-93
39. Guevara-Patino JA, Turk MJ, Wolchok JD, Houghton AN. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res 2003;90: 157-77
40. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996;157(6):2539-48
41. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160(4): 1750-8
42. Keogh EJ, Fikes J, Southwood S, et al. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001;167(2):787-96
43. Trojan A, Witzens M, Schultze JL, et al. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 2001; 61(12):4761-5
44. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 1993;14(12):602-9
45. Loftus DJ, Squarcina P, Nielsen MB, et al. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/ melanocyte epitope MART127-35. Cancer Res 1998;58(11):2433-9
46. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006;24: 419-66
47. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"- reactive tumoricidal T cells using high-affinity altered peptide ligand. J Exp Med 1998; 188(2):277-86
48. Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 1999;30(6):597-623
49. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-68
50. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 1999;96(10):5340-2
51. Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164(7):3902-12
52. Moeller M, Kershaw MH, Cameron R, et al. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res 2007;67(23):11428-37
53. Yu J, Ren X, Cao S, et al. Th1 polarization and apoptosis-inducing activity of CD4+ T-cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo. Cancer Biother Radiopharm 2006;21(3):276-84
54. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000; 164(2):562-5
55. Ohashi PS, Oehen S, Buerki K, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65(2):305-17
56. Jones T, Stem A, Lin R. Potential role of granulocyte macrophage colony stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994;13(Suppl 2): s47-53
57. Fagerberg J. Granulocyte macrophage colony stimulating factor as an adjuvant in immunotherapy. Med Oncol 1996;13(3): 155-60
58. Carlsson T, Struve J. Granulocyte macrophage colony stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine. Infection 1997;25(2): 129
59. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415
60. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996;93(20): 10972-7
61. Coumar MS, Tsia F-Y, Kanwar JR, et al. Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev 2013;39(7):802-11
62. Bos R, van Duikeren S, Morreau H, et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008;68(20):8446-55
63. Fukuda S, Pelus LM. Elevation of Survivin levels by hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells before cell cycle entry. Cell Cycle 2002;1(5):322-6
64. Zhang T, Otevrel T, Gao Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61(24):8664-7
65. Sharief MK, Semra YK. Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 2001;119(2): 358-64
66. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005;7(2):349-58
67. Ueda M, Yamashita Y, Takehara M, et al. Survivin gene expression in endometriosis. J Clin Endocrinol Metab 2002;87(7): 3452-9
68. Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, et al. Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother 2012;61(7): 967-78
69. Janetzki S, Britten CM, Kalos M, et al. "MIATA"-minimal information about T cell assays. Immunity 2009;31(4):527-8
70. Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011; 18(3):e150-7 . This review explains the rationale for active specific immunotherapy in the up-front setting.
71. Kim TG, Kim CH, Park JS, et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 2010;17(1): 143-53
72. Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med 2013;11(1):135
73. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009;58(10): 1627-34
74. Diaz Y, Tundidor Y, Lopez A, Leon K. Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response. Cancer Immunol Immunother 2013;62(3):455-69
75. Bourquin C, Schreiber S, Beck S, et al. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer 2006;118(11):2790-5